Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 4/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116199 | 0.87 | EZH2 (0.49) | EZH2MGLLCA12CA1CA2 | |
| SCHEMBL2594719 | 0.81 | EZH2 (0.49) | EZH2NPC1MGLLCA12CA1 | |
| SCHEMBL14917590 | 0.80 | EZH2 (0.48) | EZH2MGLLALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL26265512 | 0.78 | EZH2 (0.46) | EZH2MGLLCA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL7884826 | 0.73 | EZH2 (0.43) | EZH2MGLL | |
| SCHEMBL15999019 | 0.72 | NR3C2 (0.44) | EZH2NR3C2ALDH1A1KDM4EMAPT | |
| SCHEMBL2119530 | 0.71 | NPC1 (0.55) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL137907 | 0.71 | NPC1 (0.62) | NPC1CA12CA1CA2CA7 | |
| SCHEMBL4330148 | 0.71 | HTR2C (0.46) | EZH2MGLLKDM4ECYP1A2CYP2C19 | |
| SCHEMBL31188171 | 0.71 | HTR2C (0.46) | EZH2MGLLKDM4ECYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559709-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | Eisai Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| EP-0838453-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| US-6884808-B2 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6630463-B2 | Such as 4-(4-(2-(2-(5,6,7,8-tetrahydro-5,5,8,8 -tetramethylquinoxalyl))pyrrolyl))benzoic acid; for treatment of acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-10-07 | — | — | US | disclosed |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2003-07-31 | — | — | US | disclosed |
| US-6541474-B2 | Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-03-14 | — | — | US | disclosed |
| US-6329402-B1 | FOR THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA | EISAI CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-5977108-A | LEUKEMIA | EISAI CO., LTD (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0838453-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | EZH2 3357/4885NPC1 550/4885MGLL 4247/4885 |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | EZH2 3106/4885NPC1 570/4885MGLL 4140/4885 |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | EZH2 3106/4885NPC1 570/4885MGLL 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.